The New York Times (10/25, Weiland ) reported that according to new federal data, overdose deaths in the US “decreased by more than 12 percent between May 2023 and May 2024,” which represents “a major development in the nation’s efforts to combat the effects of fentanyl.” However, according to a Georgetown University analysis, the number of “fatal overdoses among Black Americans typically increased between 2022 and 2023, while deadly overdoses among white Americans often decreased.” The Times said the findings “reveal a continuation of what federal and state health officials have described as a two-track epidemic, with white Americans experiencing better outcomes and Black Americans struggling to keep up.”

Related Links:

— “The New York Times (requires login and subscription)

The Hill (10/24, Ventura) reports, “Nearly three-fourths of U.S. adults said the government is not doing enough to ensure access to affordable mental health care, a new West Health-Gallup Healthcare surveyfound.” The new “survey revealed that 73 percent of Americans said that the government was not doing enough to ensure affordable access to mental health care, compared to 12 percent who said that it was doing about the right amount.” About 7% “said the government was doing too much, while another 7 percent said they didn’t know.”

Related Links:

— “Most say not enough being done to ensure affordable mental health care: Survey,” Juliann Ventura, The Hill, October 24, 2024

HealthDay (10/24, Thompson ) reports, “Suicide risk is highest on Monday in the United States and around the world, an international team of researchers has discovered.” The researchers said, “Mondays and New Year’s Day were both associated with increased suicide risk in most countries.” Study results indicate that “Mondays constitute 15% to 18% of total suicides, compared with other days.” Study “results also show that weekend suicide risk varies greatly between countries.” The findings were published in the BMJ.

Related Links:

— “One Day of the Week Has Highest Suicide Risk,” Dennis Thompson, HealthDay, October 24, 2024

Healio (10/23, Cooper ) reports, “A single saline injection, openly prescribed as a placebo, yielded approximately 1 month of chronic back pain improvement, along with longer-term benefits in depression and sleep, according to data.” The investigators “described the placebo injection’s pain relief benefit as ‘modest in magnitude’ but clinically significant and comparable with the effect sizes of typical treatments such as NSAIDs, but with fewer adverse events.” The findings were published in JAMA Network Open.

Related Links:

— “Open-label placebo injection demonstrates ‘modest’ benefit in chronic back pain,” Justin Cooper, Healio, October 23, 2024

ABC News (10/23, Kindelan ) reports, “Thousands of bottles of a popular antidepressant medication are being recalled due to the presence of what the National Library of Medicine describes as a toxic chemical, according to a notice from the U.S. Food and Drug Administration.” The recall impacts “the medication duloxetine, which is sold under the brand name Cymbalta, according to the FDA’s notice of the voluntary recall, which began Oct. 10.” The recalled “capsules were found to contain a higher level of N-nitroso-duloxetine than is permitted, according to the recall notice.”

USA Today (10/23, Ardrey ) reports the FDA “announced a Class II recall for more than 7,000 bottles of” the antidepressant. The drug “was distributed across the country and manufactured by Towa Pharmaceutical Europe.”

Related Links:

— “Thousands of bottles of popular antidepressant recalled: 3 things to know,” Katie Kindelan, ABC News, October 23, 2024